Among ICs, programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1) and lymphocyte activation gene-3 (LAG-3) are attractive targets in immunotherapy, as they play an important role in various malignancies where they can attenuate the host immune response to tumor cells. This evidence concerns the gene PDCD1 and neoplasm.